Home LiteratureArticle Details
PMID: 19682321 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Intrathecal ziconotide for neuropathic pain: a review.

Pain practice : the official journal of World Institute of Pain ·Vol. 9 ·No. 5 ·2009-00-00 ·Pages 327-37

Rauck RL, Wallace MS, Burton AW, Kapural L, North JM

Abstract

Neuropathic pain is a considerable burden that affects activities of daily living. The management of neuropathic pain can be challenging because of multiple etiologies and complex manifestations. Ziconotide is a nonopioid intrathecal (IT) analgesic option for patients with neuropathic pain refractory to conventional treatments. The objective of this article is to review the published literature on ziconotide for the treatment of neuropathic pain. Relevant publications were identified through searches of all years of 6 databases, which included PubMed, EMBASE, and CINAHL. Search terms used were ziconotide, SNX-111, MVIIA, Prialt, and neuropathic pain. Publications were included if ziconotide was intrathecally administered (either alone or in combination with other IT agents) to treat neuropathic pain of any etiology and if pain assessment was an outcome measure. Data extracted included study design, IT drug doses, pain outcome measures, and adverse events (AEs). Twenty-eight articles met the inclusion criteria: 5 were preclinical studies and 23 were clinical studies. In the preclinical studies, ziconotide demonstrated antiallodynic effects on neuropathic pain. Data from double-blind, placebo-controlled (DBPC) trials indicated that patients with neuropathic pain reported a mean percent improvement in pain score with ziconotide monotherapy that ranged from 15.7% to 31.6%. A low starting dose and slow titration of ziconotide resulted in an improved safety profile in the aforementioned trials. Common AEs associated with ziconotide include nausea and/or vomiting, dizziness, confusion, urinary retention, and somnolence. Evidence from DBPC trials, open-label studies, case series, and case studies suggests that ziconotide, as either monotherapy or in combination with other IT drugs, is a potential therapeutic option for patients with refractory neuropathic pain. Additional studies are needed to establish the long-term efficacy and safety of ziconotide for neuropathic pain.

MeSH Terms
Analgesics, Non-Narcotic/therapeutic use Clinical Trials as Topic Female Humans Injections, Spinal/methods Male Nervous System Diseases/complications,drug therapy Pain/drug therapy,etiology Pain Measurement omega-Conotoxins/therapeutic use
Chemicals
Analgesics, Non-Narcotic omega-Conotoxins ziconotide
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Rauck Richard L
Wake Forest University Health Sciences, Winston-Salem, North Carolina 27103, USA. [email protected]
Wallace Mark S
Burton Allen W
Kapural Leonardo
North James M
Article Info
Journal
Pain practice : the official journal of World Institute of Pain
Abbr.
Pain Pract
ISSN
1533-2500
Published
2009-00-00
Epub
2009-00-03
Pages
327-37
Language
English
Region
United States
NLM ID
101130835
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]